Cabozantinib (Cabometyx) is an effective first treatment for people with metastatic papillary renal cell carcinoma (PRCC), a rare type of kidney cancer. A clinical trial showed the drug was more effective than the current standard treatment.
Combining text messaging with free at-home screening tests helped increase screening for colorectal cancer among underserved populations, results from a recent clinical trial showed. In the study, approximately 90% of the participants were Black and many were on Medicaid or uninsured, a population in which screening rates have traditionally been low. The study is part of a larger effort to reduce disparities in cancer screening.
For some men with prostate cancer, a genetic biomarker test called Decipher may help predict if their cancer will spread elsewhere in the body. Using data from an NCI-sponsored clinical trial, researchers found that people with higher Decipher scores were more likely to have cancer that spread years later and to die from the cancer. The test could help determine whether hormone therapy is needed.
For some people with estrogen receptor‒positive breast cancer, a new imaging test may help guide decisions about receiving hormone therapy, according to results of a small NCI-funded clinical study. The test can show whether estrogen receptors in tumors are active and responsive to estrogen.
Clinical Trials Information for Patients and Caregivers
Patient safety is paramount to conducting any clinical trial. This page discusses some of the ways that people who take part in clinical trials are protected.
Informed consent is a process through which prospective clinical trial participants learn details about the trial before deciding whether to take part. Learn more about this critical part of ensuring patient safety in research.
Children are not legally able to give informed consent until they turn 18. Before taking part in a clinical trial, they are asked for their assent, which means that they agree to take part. Learn more about children’s assent to participate in clinical trials.
This phase 2 trial will study how well the addition of radium-223 dichloride (Xofigo) to the chemotherapy drug paclitaxel works in treating patients with advanced breast cancer that has spread (metastasized) to the bones. The radioactive particles in radium-223 dichloride act on bone metastases, killing tumor cells and reducing the pain that the tumors can cause. Researchers want to see if this treatment will help prevent cancer from getting worse.
This phase 2 trial studies how well a combination of three or four experimental immunotherapy treatments works for people with advanced small intestine cancer or colorectal cancer that have either come back after or not responded to previous treatment. Doctors want to see if either combination helps shrink tumors in people with these advanced cancers who have not received a common type of immunotherapy called immune checkpoint inhibitors.
This phase 1/2 trial will test the addition of two experimental immunotherapy drugs to docetaxel chemotherapy for men with metastatic prostate cancer. In the phase 1 part of the trial, doctors will examine the safety of the drugs when given together. The phase 2 part will determine if the drug combination improves outcomes, specifically PSA levels in men with castration-sensitive prostate cancer and how long it takes for the cancer to get worse in men with castration-resistant prostate cancer.
